Human leukocyte antigen (HLA)-B, DRB1, and DQB1 allotypes associated with disease and protection of trachoma endemic villagers

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 4, 2009, Pages 1734-1738

  Abbas, Muneer ^a   Bobo, Linda D ^b   Hsieh, Yu Hsiang ^c   Berka, Noureddine ^d   Dunston, Georgia ^a   Bonney, George E ^a   Apprey, Victor ^a   Quinn, Thomas C ^e,f   West, Sheila K ^e  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CALGARY LABORATORY SERVICES   (Canada)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; OUTER MEMBRANE PROTEIN; PROTEIN MOMP 1; UNCLASSIFIED DRUG; BACTERIAL DNA; HLA DQ ANTIGEN; HLA DRB1*11 ANTIGEN; HLA-DRB1*11 ANTIGEN; OMP1 PROTEIN, CHLAMYDIA TRACHOMATIS; PORIN;

ADULT; ALLOTYPE; ARTICLE; BLINDNESS; CD4+ T LYMPHOCYTE; CHEEK; CHLAMYDIA TRACHOMATIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA PURIFICATION; ENDEMIC DISEASE; ENZYME IMMUNOASSAY; FEMALE; GENE FREQUENCY; HLA TYPING; HUMAN; MAJOR CLINICAL STUDY; MALE; PARENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTECTION; SIBLING; TRACHOMA; TRICHIASIS; ADOLESCENT; ALLELE; FLOW CYTOMETRY; GENETICS; GENOTYPE; HISTOCOMPATIBILITY TEST; MOUTH MUCOSA; NUCLEIC ACID HYBRIDIZATION; PATHOGENICITY; RURAL POPULATION; TANZANIA;

ADOLESCENT; ADULT; ALLELES; CHLAMYDIA TRACHOMATIS; DNA, BACTERIAL; ENDEMIC DISEASES; FEMALE; FLOW CYTOMETRY; GENE FREQUENCY; GENOTYPE; HISTOCOMPATIBILITY TESTING; HLA-B ANTIGENS; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; MOUTH MUCOSA; NUCLEIC ACID HYBRIDIZATION; PORINS; RURAL POPULATION; TANZANIA; TRACHOMA;

EID: 64049086407     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2053     Document Type: Article

References (42)

1. Making progress toward the global elimination of blinding trachoma: WHO Alliance for the Global Elimination of Blinding Trachoma by 2020. WHO Annual Meeting; 2006; Geneva, Switzerland.
2. Frick KD, Hanson CL, Jacobson GA. Global burden of trachoma and economics of disease. Am J Trop Med Hyg. 2003;69(suppl):1-10.
3. Taylor HR, Katala S, Munoz B, Turner V. Increase in mortality associated with blindness. Bull World Health Organ. 1991;69(3):335-338.
4. Jansen E, Baltussen RMPM, van Doorslaer E, et al. An eye for inequality: how trachoma relates to poverty in Tanzania and Vietnam. Ophthalmol Epidemiol. 2007;14(5):278-287.
5. Emerson PM, Burton M, Solomon AW, Bailey R, Mabey D. The SAFE strategy for trachoma control: using operational research for policy planning and implementation. Bull World Health Organ. 2006;84(8):613-619.
6. Frick KD, Colchero MA, Dean D. Modeling the economic net benefit of a potential vaccination program against ocular infection with Chlamydia trachomatis. Vaccine. 2004;22(46-47):690-697.
7. Hotez PJ, Ferris MT. The antipoverty vaccines. Vaccine. 2006;24(31-32):5787-5799.
8. Congden N, West SK, Vitale S, Katala S, Mmbaga BBO. Exposure to children and risk of active trachoma in Tanzanian women. Am J Epidemiol. 1993;137(3):366-372.
9. Hsieh Y-H, Bobo LD, Quinn TC, West SK. Risk factors for trachoma: 6-year follow-up of children aged 1 and 2 years. Am J Epidemiol. 2000;152(3):204-211.
10. Bobo LD, Novak N, Munoz B, Hsieh Y-H, Quinn TC, West S. Severe disease in children with trachoma is associated with persistent Chlamydia trachomatis infection. J Infect Dis. 1997;176(6):1524-1530.
11. Munoz B, Bobo L, Mkocha H, Lynch M, Hsieh Y-H, West SK. Incidence of trichiasis in a cohort of women with and without scarring. Int J Epidemiol. 1999;28(6):1167-1171.
12. Smith A, Munoz B, Hsieh Y-H, Bobo L, Mkocha H, West S. OmpA genotypic evidence for persistent ocular Chlamydia trachomatis infection in Tanzanian women. Ophthalmol Epidemiol. 2001;8(2-3):127-135.
13. Taylor HR, Siler JA, Mkocha HA, Munoz B, West S. The natural history of endemic trachoma: a longitudinal study. Am J Trop Med Hyg. 1992;46(5):552-559.
14. Gervassi AL, Grabstein KH, Probst P, Hess B, Alderson MR, Fling SP. Human CD8 T cells recognize the 60-kDa cysteine-rich outer membrane protein from Chlamydia trachomatis. J Immunol. 2004;173(11):6905-6913.
15. Goodall JC, Yeo G, Huang M, Rayzraschi R, Gaston JS. Identification of Chlamydia trachomatis antigens recognized by human CD4+ T lymphocytes by screening an expression library. Eur J Immunol. 2001;31(5):1513-1522.
16. Holland MJ, Faal N, Sarr I, et al. The frequency of Chlamydia trachomatis major outer membrane protein-specific CD8+ T lymphocytes in active trachoma is associated with current ocular infection. Infect Immun. 2006;74(3):1565-1572.
17. Kim S-K, Devine L, Angevine M, DeMars R, Kavathas PB. Direct detection and magnetic isolation of Chlamydia trachomatis major outer membrane protein-specific CD8+ CTLs with HLA class I tetramers. J Immunol. 2000;165(12):7285-7299.
18. Matyszak MK, Gaston Hill JS. Chlamydia trachomatis-specific human CD8+ T cells show two patterns of antigen recognition. Infect Immun. 2004;72(8):4357-4367.
19. Murthy AK, Cong Y, Murphey C, et al. Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele. Infect Immun. 2006;74(12):6722-6729.
20. Turner V, West SK, Munoz B, Taylor HR. Risk factors for trichiasis in women in Kongwa Tanzania: a case control study. Int J Epidemiol. 1993;22(2):341-347.
21. Hsieh Y-H, West SK, Bobo L, Munoz B, Quinn TC. Genotypic evidence of household transmission of Chlamydia trachomatis in a trial for trachoma control. Infectious Diseases Society of America 39th Annual Meeting, San Francisco, CA, October 25-28, 2001
22. Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. Bull World Health Organ. 1987;65(4):477-483.
23. Bobo L, Munoz B, Viscidi R, Quinn T, Mkocha H, West SK. Diagnosis of Chlamydia trachomatis eye infection in Tanzania by polymerase chain reaction/enzyme immunoassay. Lancet. 1991;338(8771):847-850.
24. Lasken RS, Egholm M. Whole genome amplification: abundant supplies of DNA from precious samples or clinical specimens. Trends Biotechnol. 2003;21(12):531-535.
25. Richards B, Skolesky J, Shumer AP, et al. Multiplex PCR amplification of the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet. 1993;2(2):159-163.
26. Saftlas AF, Waldschmidt M, Logsden-Sackett N, Triche E, Field E. Optimizing buccal cell DNA yields in mothers and infants for human leukocyte antigen genotyping. Am J Epidemiol. 2004;160(1):77-84.
27. Engelmark M, Beskow A, Magnusson J, Erlich H, Gyllensten U. Affected sib-pair analysis of the contribution of HLA class I and class II loci to development of cervical cancer. Hum Mol Genet. 2004;13(17):1951-1958.
28. Schachter J, West SK, Mabey D, et al. Azithromycin in control of trachoma. Lancet. 1999;354(9179):630-635.
29. Loomis WP, Starnbach MN. Chlamydia trachomatis infection alters the development of memory CD8+ T cells. J Immunol. 2006;177(6):4021-4027.
30. Cohen CR, Gichui J, Rukaria R, Sinei SS, Gaur LK, Brunham RC. Immunogenetic correlates for Chlamydia trachomatis-associated tubal infertility. Obstet Gynecol. 2003;101(3):438-444.
31. Ness RB, Brunham RC, Shen C, Bass DC. Associations among human leukocyte antigen (HLA) class II DQ variants, bacterial sexually transmitted diseases, endometritis, and fertility among women with clinical pelvic inflammatory disease. Sex Transm Dis. 2004;31(5):301-304.
32. White AG, Bogh J, Leheny W, et al. HLA antigens in Omanis with blinding trachoma: markers for disease susceptibility and resistance. Br J Ophthalmol. 1997;81(6):431-434.
33. Dubaniewicz A, Moszkowska G, Szczerkowska Z. Frequency of DRB1-DQB1 two-locus haplotypes in tuberculosis: preliminary report. Tuberculosis. 2005;85(4):259-267.
34. Sadahiro A, Roque AC, Shikanai-Yasuda MA. Generic human leukocytes antigen class II (DRB1 and DQB1) alleles in patients with paracoccidiomycosis. Med Mycol. 2007;45(1):35-40.
35. Kryczka W, Brojer E, Kalinska A, Urbaniak A, Zarebska-Michaluk D. DRB1 alleles in relation to severity of liver disease in patients with chronic hepatitis C. Med Sci Monit. 2001;7(suppl 1):217-220.
36. Thio C, Carrington M, Marti D, et al. Class II HLA alleles and hepatitis B persistence in African Americans. J Infect Dis. 1999;179(4):1004-1006.
37. Borghans JAM, Beltman JB, DeBoer RJ. MHC polymorphism under host-pathogen coevolution. Immunogen. 2004;55(11):732-739.
38. Prugnolle F, Manica A, Charpentier M, et al. Pathogen-driven selection and worldwide HLA class I diversity. Curr Biol. 2005;15(11):1022-1027.
39. Brunham RC, Yang I, Macclean I, Kimani J, Maitha G, Plummer F. Chlamydia trachomatis from individuals in a sexually transmitted disease core group exhibit frequent sequence variation in the major outer membrane protein (omp1) gene. J Clin Invest. 1994;94(1):458-463.
40. Millman KL, Tavare S, Dean D. Recombination in the ompA gene but not the omcB gene of Chlamydia contributes to serovar-specific differences in tissue tropism, immune surveillance, and persistence of the organism. J Bacteriol. 2001;183(20):5997-6008.
41. Dean D, Kandel RP, Adhikari HK, Hessel T. Multiple Chlamydiaceae species in trachoma: implications for disease pathogenesis. PLOS Med. 2008;5(1):57-69.
42. Telyatnikova N, Gaston JSH. Prior exposure to infection with Chlamydia pneumoniae can influence the T-cell mediated response to Chlamydia trachomatis. FEMS Immunol Med Microbiol. 2006;47(2):190-198.